Evoqua Water Technologies (NYSE:AQUA) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Evoqua Water Technologies Corp. is a provider of mission critical water treatment solutions. The company offer services, systems and technologies to support customers’ full water lifecycle. Its operating segment consists of Industrial, Municipal and Products. Industrial Segment provides fully-integrated systems and service solutions. Municipal Segment provides engineered solutions and equipment for the treatment of wastewater, purification of drinking water and odor and corrosion control for municipalities. Products Segment sells differentiated technologies to a diverse set of water treatment system specifiers, integrators and end users globally. Evoqua Water Technologies Corp. is based in PITTSBURGH, United States. “
A10 Networks (NYSE:ATEN) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $17.00 price target on the stock. According to Zacks, “A10 Networks, Inc. provides software based application networking solutions. Its solutions enable enterprises, service providers, Web giants, and government organizations to enhance, secure, and optimize the performance of their data center applications and networks. The company delivers its solutions on optimized hardware appliances and as virtual appliances across its Thunder Series and AX Series product families. A10 Networks, Inc. is headquartered in San Jose, California. “
Credit Suisse Group AG initiated coverage on shares of Axon Enterprise (NASDAQ:AXON). They issued an outperform rating and a $169.00 price target on the stock.
Aziyo Biologics (NASDAQ:AZYO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aziyo Biologics Inc.is a regenerative medicine company. It focuses on the development of regenerative medical products to address the implantable electronic device/cardiovascular, orthopedic/spinal repair, and soft tissue reconstruction markets. The company operates principally in Roswell, Georgia; and Richmond, California. Aziyo Biologics Inc.is based in Silver Spring, Maryland. “
Brookfield Asset Management (NYSE:BAM) (TSE:BAM.A) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Brookfield Asset Management Inc. is an asset manager. Focused on property, power and infrastructure assets, the company has assets under management and is co-listed on the New York and Toronto Stock Exchanges under the symbol BAM. At Brookfield they continually strive to ensure that they have sound corporate governance practices to maintain investor confidence in the way in which they do business. To ensure it communicates with there practices and commitment to strong corporate governance, they are proud to share with its Statement of Corporate Governance, Corporate Disclosure Policy, Code of Business Conduct and Ethics and other related information on its corporate governance initiatives and practices. “
BigBear.ai (NYSE:BBAI) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “BigBear.ai is a provider of artificial intelligence, machine learning, cloud-based big data analytics, and cyber engineering solutions. BigBear.ai, formerly known as GigCapital4 Inc., is based in COLUMBIA, Md. “
Barrett Business Services (NASDAQ:BBSI) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $88.00 price target on the stock. According to Zacks, “BARRETT BUSINESS SERVICES INC. provides light industrial, clerical and technical employees to a wide range of businesses through staff leasing, contract staffing, site management and temporary staffing arrangements. The Company provides employees to a diverse set of customers, including among others, forest products and agriculture-based companies, electronics manufacturers, transportation and shipping enterprises, professional firms and general contractors. “
Bath & Body Works (NYSE:BBWI) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Bath & Body Works is a specialty retailers and home to America’s Favorite Fragrances(R) offering exclusive fragrances for the body and home, fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap. Bath & Body Works, formerly known as L BRANDS INC, is based in COLUMBUS, Ohio. “
Atreca (NASDAQ:BCEL) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atrecas approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets. “
BioCryst Pharmaceuticals (NASDAQ:BCRX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $10.00 price target on the stock. According to Zacks, “BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries. “
Bicycle Therapeutics (NASDAQ:BCYC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom. “
DBV Technologies (NASDAQ:DBVT) was downgraded by analysts at The Goldman Sachs Group, Inc. from a buy rating to a neutral rating. They currently have $1.50 target price on the stock, down from their previous target price of $6.00.
Palantir Technologies (NYSE:PLTR) was downgraded by analysts at Royal Bank of Canada from a sector perform rating to an underperform rating.
Credit Suisse Group AG started coverage on shares of Tyler Technologies (NYSE:TYL). They issued a neutral rating and a $408.00 price target on the stock.
Receive News & Ratings for Evoqua Water Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoqua Water Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.